Gallego Mónica, Zayas-Arrabal Julián, Alquiza Amaia, Apellaniz Beatriz, Casis Oscar
Department of Physiology, Faculty of Pharmacy, University of the Basque Country UPV/EHU, Vitoria-Gasteiz, Spain.
Front Pharmacol. 2021 Jul 8;12:687256. doi: 10.3389/fphar.2021.687256. eCollection 2021.
Diabetes is a chronic metabolic disease characterized by hyperglycemia in the absence of treatment. Among the diabetes-associated complications, cardiovascular disease is the major cause of mortality and morbidity in diabetic patients. Diabetes causes a complex myocardial dysfunction, referred as diabetic cardiomyopathy, which even in the absence of other cardiac risk factors results in abnormal diastolic and systolic function. Besides mechanical abnormalities, altered electrical function is another major feature of the diabetic myocardium. Both type 1 and type 2 diabetic patients often show cardiac electrical remodeling, mainly a prolonged ventricular repolarization visible in the electrocardiogram as a lengthening of the QT interval duration. The underlying mechanisms at the cellular level involve alterations on the expression and activity of several cardiac ion channels and their associated regulatory proteins. Consequent changes in sodium, calcium and potassium currents collectively lead to a delay in repolarization that can increase the risk of developing life-threatening ventricular arrhythmias and sudden death. QT duration correlates strongly with the risk of developing , a form of ventricular tachycardia that can degenerate into ventricular fibrillation. Therefore, QT prolongation is a qualitative marker of proarrhythmic risk, and analysis of ventricular repolarization is therefore required for the approval of new drugs. To that end, the Thorough QT/QTc analysis evaluates QT interval prolongation to assess potential proarrhythmic effects. In addition, since diabetic patients have a higher risk to die from cardiovascular causes than individuals without diabetes, cardiovascular safety of the new antidiabetic drugs must be carefully evaluated in type 2 diabetic patients. These cardiovascular outcome trials reveal that some glucose-lowering drugs actually reduce cardiovascular risk. The mechanism of cardioprotection might involve a reduction of the risk of developing arrhythmia.
糖尿病是一种慢性代谢性疾病,在未接受治疗时其特征为高血糖。在与糖尿病相关的并发症中,心血管疾病是糖尿病患者死亡和发病的主要原因。糖尿病会引发一种复杂的心肌功能障碍,称为糖尿病性心肌病,即使在没有其他心脏危险因素的情况下,也会导致舒张和收缩功能异常。除了机械异常外,电功能改变是糖尿病心肌的另一个主要特征。1型和2型糖尿病患者通常都会出现心脏电重构,主要表现为心电图中可见的心室复极延长,即QT间期延长。细胞水平的潜在机制涉及几种心脏离子通道及其相关调节蛋白的表达和活性改变。钠、钙和钾电流的相应变化共同导致复极延迟,这可能会增加发生危及生命的室性心律失常和猝死的风险。QT间期与发生尖端扭转型室速(一种可恶化为心室颤动的室性心动过速形式)的风险密切相关。因此,QT延长是心律失常风险的定性标志物,因此新药获批需要分析心室复极情况。为此,全面QT/QTc分析评估QT间期延长以评估潜在的心律失常作用。此外,由于糖尿病患者死于心血管原因的风险高于非糖尿病个体,因此必须在2型糖尿病患者中仔细评估新型抗糖尿病药物的心血管安全性。这些心血管结局试验表明,一些降糖药物实际上可以降低心血管风险。心脏保护机制可能包括降低心律失常的发生风险。